Marijuana stock GW Pharmaceuticals nabs DEA Schedule V

9/27/18–The Drug Enforcement Agency (DEA) has awarded GW Pharmaceuticals’ epilepsy drug, Epidiolex, Schedule V status, its least restrictive classification. The decision clears the way for GW Pharmaceuticals to begin offering the only CBD oil that’s cleared by the DEA for use nationwide, and it puts the company on a path to disrupt how doctors treat patients who fail to respond to existing anti-epilepsy medications.